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ABSTRACT: Introduction: The written information on medicines has been acknowledged as an important 
tool for health education. Objective: To analyze the use and understanding of  medicine package inserts by 
users and assess sociodemographic and medical factors associated with their comprehension. Method: Data in 
this analysis are part of  the PNAUM National Survey — a cross-sectional population-based study conducted 
in Brazil. Descriptive statistics and the Pearson χ2 tests were performed to compare proportions between 
sociodemographic and medical characteristics, as well as use and understanding of  medicine package inserts. 
Results: A total of  28.427 individuals responded to questions related to medicine package inserts. From these, 
59.6% (95%CI 57.7 – 61.5) said they usually read the inserts, and 98.4% (95%CI 98.0 – 98.8) considered them 
necessary. Among people who read the medicine package inserts, more than half  indicated difficulties with 
legibility (57.4%; 95%CI 55,2 – 59,6) and readability (54.1%; 95%CI 52.1 – 56.1). People from a lower education 
level reported greater difficulty in understanding them. Conclusion: The larger portion of  the population 
usually read medicine package inserts. Nevertheless, people have difficulty in reading and understanding them.
Keywords: Medicine package inserts. Health communication. Readability.
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INTRODUCTION
In several countries, the written information on medicines has been acknowledged as 
an important tool for health education, and their drug regulatory agencies have estab-
lished guidelines and standards for the production and delivery of  medicine package 
inserts (MPI).
In European Union, all medicinal products placed on the market must be accompanied 
by MPI containing text that is demonstrably clear and simple1,2. In the United States there 
are three types of  written materials that accompany medicines, of  which two (Medication 
Guides and Patient package inserts) are developed by the pharmaceutical industry, regulated 
and approved by the Food and Drug Administration (FDA). A third format (Consumer med-
ication information) is developed by commercial providers, and it is distributed in pharma-
cies and not reviewed by the FDA2-4. In Brazil, MPI is the same for all products registered 
as medicines. The manufacturer produces one MPI for the health professional and another 
one for the patient, and the National Agency of  Sanitary Surveillance (ANVISA) is respon-
sible for the approval of  these materials’ format and content5. 
Due to the complexity and importance of  medicine information, technical standards 
and guidelines that establish the format and content have been improved in many coun-
tries to make the leaflet more attractive and understandable to the user. Among several 
factors, the proper use of  the medicine package insert depends on its readability and the 
user’s ability to read, understand and use the information contained therein for the ratio-
nal use of  the medicine6. Some studies have reported that health literacy is outstanding 
among the individual factors related to the difficulties in understanding the information 
contained in the MPI7,8.
RESUMO: Introdução: A informação escrita sobre medicamentos tem sido reconhecida como uma ferramenta 
importante para a educação em saúde. Objetivo: Analisar o uso e compreensão de bulas de medicamentos pelos 
usuários e avaliar fatores sociodemográficos e médicos associados ao seu uso e compreensão. Método: Os dados nesta 
análise fazem parte da PNAUM — um estudo transversal de base populacional realizado nas cinco regiões brasileiras. 
Estatísticas descritivas e teste de χ2 de Pearson foram utilizados para comparar proporções entre características 
sociodemográficas e médicas, uso e compreensão das bulas. Resultados: Um total de 28.427 indivíduos responderam 
a questões relativas a bulas. Desse total, 59,6% (IC95% 57,7 – 61,5) responderam que geralmente leem as bulas 
e 98,4% (IC95% 98,0 – 98,8) as consideraram necessárias. Entre as pessoas que leram as bulas, mais da metade 
indicou dificuldades de legibilidade (57,4%; IC95% 55,2 – 59,6) e de leiturabilidade (54,1%; IC95% 52,1 – 56,1) das 
bulas. As pessoas com menos educação relataram maior dificuldade em compreendê-las. Conclusões: A maioria 
da população tem o costume de ler as bulas, no entanto as pessoas consideram-nas difíceis de ler e compreender.
Palavras-chave: Bulas de medicamentos. Comunicação em saúde. Compreensão.
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Evaluating aspects related to the use and understanding of  the MPI from the user’s 
point of  view may help to improve this document as an educational material. This study 
aimed to describe its use and understanding by users and to evaluate the associated socio-
demographic factors.
METHOD
The data of  the present analysis are part of  the National Survey on Access, Use and 
Promotion of  Rational Use of  Medicines (PNAUM), a cross-sectional population-based 
study conducted in Brazil. The studied population consisted of  people living in permanent 
private households in the urban area of  the five Brazilian regions. We used a questionnaire 
containing 11 blocks, answered by the participants at their residence, by using an electronic 
device for data collection, storage and transmission9.
The sample included eight demographic domains (different genders and age ranges) that 
were replicated for each of  the five Brazilian geographic regions, resulting in 40 domains. 
As a result, the sample size calculated was 960 per domain, totaling 38,400 interviewees. 
The sample was selected in three stages: municipality (primary unit), census tract and domi-
cile. Its process was complex and resulted in a sample that guaranteed national represen-
tativeness. Sample composition, procedures and other methodological details of  PNAUM 
are available in the research’s methodological article9.
The use and understanding of  the MPI by the participants was investigated in a specific 
block. In the pre-testing phase, some questions were initially asked openly and in subsequent 
stages transformed into multiple choice questions. This block was answered only by liter-
ate individuals; were aged 15 years or older; and did not fit into the concept of  “incapable 
people” (people unable to communicate or provide information about themselves due to 
physical or mental illness, speech deprivation or lack of  judgment to answer the questions).
The use of  MPIs was evaluated by means of  the dichotomous question: “(a) Do you usu-
ally read the MPI of  the medicines you use?”. If  not, the participants were asked why they 
did not read it. Participants who answered affirmatively to this question were asked subse-
quent questions about legibility (“Seeing what is written in the medicine package insert, it 
is”, with the following alternative answers: ‘very difficult’, ‘quite difficult’, ‘not difficult’); 
and on the MPI’s readability (“Understanding what is written in MPI is”, followed by fol-
lowing alternative answers: ‘very difficult’, ‘quite difficult’, and ‘not difficult’).
Participants who reported having the habit of  reading the MPI were asked to give their 
opinion about the need for it and the reasons why they considered them to be necessary. 
Finally, participants were asked if  they had stopped taking some medicine after reading its MPI.
The main outcome variables analyzed were:
• habit of  reading the MPI (yes / no);
• difficulty in understanding the MPI (“No”, for those who answered that understanding 
the MPI was not difficult; and “yes”, for those who answered that understanding it 
was very difficult or quite difficult).
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The demographic and socioeconomic characteristics analyzed were: gender (female / 
male), schooling (did not go to school, 1 to 8 years of  schooling and more than 8 years 
of  schooling), age (15 to 19 years, 20 to 39 years, 40 to 59 years and > 60 years), major 
Brazilian geographical regions (North, Northeast, Southeast, South and Midwest) and 
economic classification by the Brazilian Economic Classification Criterion (CCEB) of  
Brazilian Association of  Survey Companies (ABEP). This classification evaluates the 
amount of  goods purchased and the educational level of  household heads by scoring 
from zero to forty-six, and the respondents were distributed into eight economic classes 
(A1, A2, B1, B2, C1, C2, D and E).
The medical variables analyzed were: use of  medication (use of  at least one medica-
tion for chronic disease, occasional or contraceptive use) (yes / no); use of  medicines for 
chronic diseases (use of  at least one medication for chronic diseases) (yes /no); and use of  
medications for acute / occasional diseases (use of  at least one drug to treat acute signs, 
symptoms and conditions) (yes/no).
Descriptive analyses were performed and the results expressed in frequency and 95% 
confidence interval (95%CI). Pearson’s χ2 test was used to compare proportions between 
sociodemographic characteristics and the use and understanding of  medicine package 
inserts, with a P-value < 0.05 being considered statistically significant.
These data were stored in SPSS software, version 18.0 for Windows (SPSS Inc., Chicago, 
IL, USA), by using the appropriate set of  commands for complex samples’ analysis and guar-
anteeing the necessary weighting considering the sample’s design. 
The project was approved by the National Research Ethics Commission (CONEP). 
Participants were interviewed only after we had obtained their permission, by means of  
the Term of  Free and Informed Consent signed by both the researcher and the participant.
RESULTS
The initial sample in the PNAUM was 41,433 individuals, of  whom 28,427 met the inclu-
sion criteria to answer the questions related to the medication package leaflets (literate indi-
viduals, aged 15 years or older and able), by whom the sample analyzed in this study was 
composed. 
From this total, 59.6% (95%CI 57.7 – 61.5) stated that they usually read the MPI. The rea-
sons for not reading MPI are shown in Table 1. The non-use of  medication was the main rea-
son cited (40%), followed by reading difficulty (31%) and size (extension) of  the material (20%).
Among those who read the MPI, more than half  found it difficult to see (57.4%; 95%CI 
55,2 – 59,6) and understand (54.1%; 95%CI 52.1 – 56.1) what was written in it (Table 2).
After reading the MPI, 25.0% (95%CI 23.5 – 26.7) of  the interviewees stopped taking 
some of  the medicines. Despite the fact that almost half  the respondents did not read the 
MPI, 98.4% (95%CI 98.0 – 98.8) of  the individuals who answered this questionnaire con-
sidered it to be necessary. The main reasons of  this opinion were related to the presence of  
information about indication (79.6%) and contraindications (75.4%) (Table 3).
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Table 1. Medicine users’ habit of reading medicine package inserts (n = 28,427) and reasons for 
not reading them*.
% (95%CI)
Habit of Reading the medicine package inserts
Yes (n = 17.244) 59.6 (57.7 – 61.5)
No (n = 11.183) 40.4 (38.5 – 42.3)
Reasons for not reading the medicine package inserts*
I do not use medicines 40
They are difficult to read 31
They are too long 20
They confuse 15
Trust the doctor 2
Do not see/ Do not read 2
Others 6
*The total exceeds 100% because participants could choose more than one answer option. It was not possible to 
calculate the CI for proportions because it is a multiple choice question. Considering the sampling plan of the PNAUM, 
only the procedure for the calculation of the confidence interval for independent samples has been implemented in 
SPSS; 95%CI: interval of confidence of 95%.
Table 2. Difficulty of legibility and readability of the medicine package inserts referred to by the users.
% 95%CI
Difficulty with seeing the print in medicine package inserts (legibility) (n = 17,244)
Very difficult 25.2 23.4 – 27.1
A little difficult 32.2 30.7 – 33.8
Is not difficult 42.6 40.4 – 44.8
Difficulty in understanding the medicine package inserts (readability) (n = 17,244)
Very difficult 17.2 15.7 – 18.9
A little difficult 36.9 35.4 – 38.5
Is not difficult 45.9 43.8 – 47.9
95%CI: interval of confidence of 95%.
The use of  MPIs according to sociodemographic and medical characteristics is pre-
sented in Table 4. There was no difference in its use when analyzed by gender and age 
group. People with lower schooling and purchasing power reported reading fewer MPIs 
than people with higher education and of  higher economic class. MPIs were read by a 
higher number of  people who reported use of  medication for acute/occasional condition 
PIZZOL, T.S.D ET AL.
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Table 3. Reasons why users considered medicine package inserts to be necessary*.
%
Show indications for use of the medicine 79.6
Show contraindications for the medicine 75.4
Show information about the composition of the medicine 53.3
Show information about the dosage and administration of the medicine 49.6
Other reasons 1.6
*The total exceeds 100% because participants could choose more than one answer option. It was not possible to 
calculate the CI for proportions because it is a multiple choice question. Considering the sampling plan of the PNAUM, 
only the procedure for the calculation of the confidence interval for independent samples has been implemented in SPSS.
than by those who did not use medication for this type of  condition. Whereas, between 
the individuals who made continuous use of  medicines and those who did not use them, 
there was no difference in these numbers. Participants from the Northeast region usually 
read medicine package inserts more frequently than participants from other regions. The 
association between sociodemographic and medical characteristics and the difficulty in 
understanding the MPI is presented in Table 5. People with fewer years of  study declared 
more difficulty in understanding the information presented in it than those with more.
DISCUSSION 
According to a previous study conducted in 1998 and published in 2000 by the authors 
of  this article10, patients considered the MPI the most important source of  information 
about medicines after medical prescription. Almost 20 years later, even with all technolog-
ical advances in the media — internet, TV, computers, smartphones, tablets and others — 
MPIs continued to be a prominent source of  information among users, and most of  the par-
ticipants had the habit of  reading them, according to the results of  our study. On the other 
hand, a significant number of  interviewees reported difficulties in reading the MPI, as they 
considered them illegible, long and confusing. Among the individuals with less schooling, 
the difficulty was greater. In agreement with other studies, our results suggested that MPIs 
were more than a legal obligation to be taken care by pharmaceutical manufactures because 
it was an important information tool for the users11-13.
According to reviews on the subject, the most important information about medicines, 
from the user’s point of  view, were: information about indication, potential adverse effects, 
dose and dosage14,15. In our study, participants emphasized MPI’s importance for provid-
ing them information on indications and contraindications. In Brazilian MPIs, these items 
are presented as answers to the questions “What is this medicine for?” and “When should 
I not use this medicine?”, respectively. This finding may indicate that people use the MPI 
to seek information on the medical condition to be treated, to confirm or supplement the 
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Table 4. Association of sociodemographic and medical characteristics, according to the habit of 
reading medicine package inserts.
Variables
Usually reads medicine 
package inserts
Does not usually read 
medicine package inserts p-value*
% 95%CI % 95%CI
Total 59.6 57.7 – 61.5 40.4 38.5 – 42.3
Gender
Female 59.4 57.3 – 61.4 40.6 38.6 – 42.7
0.660
Male 59.9 57.5 – 62.2 40.1 37.8 – 42.5
Age Group 
15 to 19 59.4 55.2 – 63.5 40.6 36.5 – 44.8
0.186
20 to 39 60.7 58.5 – 62.8 39.3 37.2 – 41.5
40 to 59 58.2 55.9 – 60.4 41.8 39.6 – 44.1
≥ 60 60.0 57.5 – 62.4 40.0 37.6 – 42.5
Schooling 
Never studied 17.9 11.3 – 27.1 82.1 72.9 – 88.7
0.000*1 to 8 years of schooling 50.8 48.7 – 52.9 49.2 47.1 – 51.3
Over 8 years of schooling 69.5 67.2 – 71.6 30.5 28.4 – 32.8
Region
North 64.1 60.5 – 67.6 35.9 32.4 – 39.5
0.000*
Northeast 66.5 64.6 – 68.4 33.5 31.6 – 35.4
Southeast 55.6 52.2 – 59.0 44.4 41.0 – 47.8
South 61.6 58.9 – 64.2 38.4 35.8 – 41.1
Midwest 57.8 54.7 – 60.9 42.2 39.1 – 45.3
Economic class (ABEP)
A/B 62.4 59.4 – 65.3 37.6 34.7 – 40.6
0.000*C 60.1 57.9 – 62.3 39.9 37.7 – 42.1
D/E 54.8 52.1 – 57.4 45.2 42.6 – 47.9
Medicine use 
Yes 60.7 58.8 – 62.6 39.3 37.4 – 41.2
0.029*
No 58.4 56.0 – 60.8 41.6 39.2 – 44.0
Continuous use of medication
Yes 59.6 57.3 – 61.8 40.4 38.2 – 42.7
0.956
No 59.6 57.7 – 61.6 40.4 38.4 – 42.3
Eventual use of medication
Yes 62.3 60.4 – 64.2 37.7 35.8 – 39.6
0.0001*
No 58.1 55.8 – 60.4 41.9 39.6 – 44.2
*χ2 test, p < 0.05; 95%CI: interval of confidence of 95%; ABEP: Brazilian Association of Survey Companies.
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Table 5. Association of sociodemographic and medical characteristics and difficulty in understanding 
the medicine package insert. 
Variables
Difficulty in understanding the medicine package insert  
p-value*Yes No
% 95%CI % 95%CI
Total 54.1 52.1 – 56.1 45.9 43.9 – 47.9
Gender
Female 53.1 50.5 – 55.6 46.9 44.4 – 49.5
0.125
Male 55.1 52.8 – 57.4 44.9 42.6 – 47.2
Age Group
15 to 19 50.8 44.9 – 56.6 49.2 43.4 – 55.1
0.147
20 to 39 55.8 53.3 – 58.4 44.2 41.6 – 46.7
40 to 59 53.2 50.7 – 55.7 46.8 44.3 – 49.3
≥ 60 53.8 50.7 – 56.9 46.2 43.1 – 49.3
Schooling 
Never studied 86.0 71.4 – 93.8 14.0 6.2 – 28.6
0.000*1 to 8 years of schooling 63.2 60.5 – 65.8 36.8 34.2 – 39.5
Over 8 years of schooling 47.2 44.7 – 49.6 52.8 50.4 – 55.3
Region
North 55.1 51.5 – 58.6 44.9 41.4 – 48.5
0.051
Northeast 57.6 54.8 – 60.4 42.4 39.6 – 45.2
Southeast 51.9 48.0 – 55.9 48.1 44.1 – 52.0
South 53.4 50.3 – 56.5 46.6 43.5 – 49.7
Midwest 57.0 53.2 – 60.8 43.0 39.2 – 46.8
Economic class (ABEP)
A/B 52.4 49.2 – 55.5 47.6 44.5 – 50.8
0.329C 54.6 52.3 – 57.0 45.4 43.0 – 47.7
D/E 55.3 51.4 – 59.1 44.7 40.9 – 48.6
Medicine use
Yes 54.8 52.4 – 57.1 45.2 42.9 – 47.6
0.360
No 53.5 50.9 – 56.0 46.5 44.0 – 49.1
Continuous use of medication
Yes 53.9 51.2 – 56.6 46.100 43.4 – 48.8
0.782
No 54.3 52.0 – 56.5 45.7 43.5 – 48.0
Eventual use of medication
Yes 55.7 53.0 – 58.3 44.3 41.7 – 47.0
0.111
No 53.3 50.9 – 55.6 46.7 44.4 – 49.1
*χ2 test, p < 0.05; 95%CI: interval of confidence of 95%; ABEP: Brazilian Association of Survey Companies.
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information received during their consultation with the doctor. Another possibility could be 
that people seek this information before self-medication, to ensure that the product meets 
their needs and has no contraindications for the intended use.
In this study we explored the concept of  legibility and readability of  MPIs and asked the 
users questions about the difficulty they had in seeing and understanding what was writ-
ten in it. Most of  the respondents stated that they had some degree of  difficulty with these 
aspects. This reinforced results from previous studies that evaluated MPIs and other written 
materials, which were conducted by the researchers themselves13 or by consumers (patients 
and health professionals)1,4,16. Among the problems of  legibility identified in the systematic 
review of  Pires et al.1, the following were outstanding: insufficiently clear and simple texts, 
use of  small print sizes and reduced number of  illustrations.
The difficulty in reading and understanding the MPI was pointed out not only by the 
readers, but also by those who stated that they did not have the habit of  reading them. 
Over 10% of  non-readers mentioned long and confusing MPIs as reasons for not using, thus 
emphasizing the deficiencies in legibility and readability of  these documents. 
The habit of  reading the MPI was directly related to some socioeconomic characteris-
tics of  the population. As the educational level declined, the MPI’s reading decreased con-
siderably. While most of  those with a higher level of  education reported that they read the 
MPI, fewer than a fifth of  those who could read, but had not gone to school usually did it. 
Among those who usually read MPIs, the majority considered it to be difficult to understand, 
even among those with higher education. Some studies have shown the need for MPI’s text 
to be simplified or clearer, suited to the users’ level of  schooling and health literacy1,6,17,18. 
MPIs were usually written at a high level of  technical language, contained scientific jargons, 
making it much more difficult for those with a lower level of  schooling or health literacy 
to understand them, as verified by Wolf  et al.8 and Davis et al.7. This difficulty could lead 
to consumers losing interest or motivation to read them.
Attitudes and practices related to self-medication can explain the higher use of  the MPI 
by individuals that reported use of  medicines for acute/occasional conditions. Consumers 
read the MPI of  over-the-counter and other medicines used by self-medication to expand 
their understanding about a medicine’s ingredients, relevant indication(s), directions for use 
and side effects16. Consequently, MPIs are probably one of  the most important sources of  
drug-related information used for practices related to self-medication.
Some countries, in addition to the norms that establish the mandatory items, MPIs must 
contain guidelines for the adequate development of  these materials, such Guideline on the 
readability of  the labelling and package leaflet of  medicinal products for human use, in European 
Union19; and Investigating Consumer Medicine Information (I-CMI) Project, in Australia20. In Brazil, 
ANVISA has developed the Medication Labeling Guide with the aim of  presenting principles 
and rules to be observed when writing the MPI to make it clearer, more concise and accessi-
ble to the user. Among the principles set out in this guide are the use of  short sentences for 
long and complicated instructions, use of  the active voice where appropriate, verbs instead 
of  names in sentences;, common language whenever possible and concrete and non-tech-
nical terms21. However, the manufacturers’ obligation to test their leaflets among potential 
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users has not yet been regulated, as in other countries. The European Medicines Agency 
(EMA), for example, states that MPI’s readability must be verified by means of  tests car-
ried out in face-to-face interviews with at least 20 users (preferably from the population for 
which the medicine is intended).
In the present study we investigated the opinion of  potential users of  medications 
on the use, usefulness and understandability of  MPIs in general, without questioning a 
particular medicine or specific items related to legibility and readability (such as letter 
size, text layout, presence of  technical terms, etc.). In addition, individuals who had not 
recently used medicine may have had different motivations to answer the questionnaire 
in comparison with individuals who take medication regularly and may have needed to 
consult the MPI.
Readability tests, applied to medicine users by the industry, before the approval of  the 
MPI by the regulatory agency, may be an alternative in the construction of  a label model 
that is suitable for most of  the population. Although MPIs are considered an important 
informative material in promoting the rational use of  medications, their benefits may be 
compromised, as they do not present information that is adequate and easily understood 
by most medicine users. 
In the present study, we found that most of  the consumers interviewed had the habit 
of  reading the MPIs, in accordance with previous studies (range 60–95%)22. However, irre-
spective of  the habit of  reading, MPIs were considered difficult to read and understand. 
This problem was aggravated among the less educated individuals, drawing attention to 
an issue that continues to be a challenge to the government and society of  several coun-
tries: the low level of  schooling of  a large part of  the population, especially in develop-
ing countries, and the inadequate health literacy. In this sense, if  people have a low level 
of  schooling and difficulty in reading and understanding health texts, there is no simple 
MPI that will solve the problem. Particularly for people with a lower level of  schooling 
or health literacy, it should be a complement, not a substitute for verbal information pro-
vided by health professionals14,22.
CONCLUSION
In conclusion, the larger portion of  the Brazilian population usually reads the MPI. 
Nevertheless, people stated that they have difficulty in reading and understanding it, espe-
cially those of  a lower educational level. Our findings can be useful for manufacturers and 
drug regulatory agencies to produce more readable and understandable MPIs to users. 
Efforts to improve their legibility and readability must be in line with efforts to improve 
education and other educational health actions that could minimize the difficulties of  spe-
cific groups of  the population, such as the elderly. In Brazil, MPIs available in audio, with 
an enlarged letter size or in braille have been regulated by sanitary legislation, offering an 
important alternative for people with visual impairment.
National Research Ethics Commission approval: CONEP, 398.131, dated 9/16/2013
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